Re: Tager and Tikly. Clinical and laboratory manifestations of systemic sclerosis (scleroderma) in Black South Africans

B. Rozman, and T. Kveder

University Medical Centre, Department of Rheumatology, Vodnikova 62, 1000 Ljubljana, Slovenia

Sir, We read with interest the article by R. E. Tager and M. Tikly entitled ‘Clinical and laboratory manifestations of systemic sclerosis (scleroderma) in Black South Africans’ [1]. The authors claimed that there had been no studies on the overall spectrum of clinical and laboratory manifestations of systemic sclerosis (SSc) in the general Black population. Unfortunately, the authors have not focused enough attention on some clinical aspects of the disease and, in particular, on the presence of autoantibodies.

The diagnostic criteria for SSc from 1980 [2] are still in use, despite knowledge of the subsets of SSc, especially of myositis-associated overlap syndromes [3] and of the distinct clinical subset associated with antibodies to RNA polymerases [4] having been significantly expanded.

Almost 20 yr have passed since the first detailed report about autoantibodies in SSc [5]. Further refinements in the methodology of autoantibody detection followed, some of them increasing the sensibility of the assays, which may, on the other hand, lessen their overall discriminatory values. Some postulates concerning the detection of autoantibodies have been accepted during the meetings of the European Workshop for Rheumatology Research—The Consensus Finding Study Group on Antibodies in Rheumatic Diseases (EWRR). They include methods which have been validated by leading European laboratories undertaking analysis of sera in the workshops. These methods have proved to be practically useful and leading to consistent inter-laboratory results [6].

Therefore, we think that several statements in the article [1] should be discussed in more detail. From the clinical point of view, the definition of myositis was weakly based, omitting electromyography, which made the authors unable to discern between inflammatory myositis and myopathy concomitant with SSc [7]. Disregarding this fact, the percentage of myositis was unusually high [1], as the frequency of myositis does not exceed 19%, even in diffuse scleroderma, according to Medsger [8].

As for the presence of specific autoantibodies inferred from the antinuclear antibody (ANA) staining pattern, it is believed that ANA patterns are only indicative. Precise determination of antibody specificities always needs confirmation by other laboratory techniques such as counterimmunoelectrophoresis (CIE), enzyme-linked immunosorbent assay (ELISA), Western blotting, RNA or protein precipitation. This holds true especially because autoimmune sera mostly contain a mixture of antibody activities at different concentrations ([9, 10] our observations on over 10 000 sera tested on Hep2 cells per year).

The speckled nuclear pattern, more precisely speckled/homogeneous nuclear staining and homogeneous staining of the chromosomes in metaphase, is indeed seen in sera with anti-Scl-70 antibodies [4, 11, 12]. In cases of polyspecific sera (containing antibodies to Ro, La, U1RNP, Sm etc.), there can be some confusion due to mixed pattern staining. In SSc overlapping with myositis, one should be extremely aware of other possible antibody specificities, i.e. against Ku, PM/Scl, fibrillarin, U1RNP, and Jo-1. Except for anti-Jo-1 these antibodies contribute similar nucleolar patterns on Hep2 cells. Anti-Ku antibody is found in 50% of patients with polymyositis–scleroderma overlap syndromes and in a high number of scleroderma patients with primary pulmonary hypertension [1315]. The antigen for antibodies against PM/Scl or nucleolin complex comprises at least 10 polypeptides, the major antigenic components having molecular weights of 75 kDa and 100 kDa. These antibodies give a similar nucleolar pattern of homogeneous nuclear staining to anti-Ku antibodies [16]. Anti-fibrillarin antibodies, highly specific for SSc associated with skeletal muscle disease and pulmonary hypertension, are more frequent in Blacks. They are directed towards the 34 kDa fibrous protein in U3 small nuclear ribonucleoprotein particles bound to DNA and involved in ribosomal RNA processing [17, 18]. Such antibodies yield a nucleolar clumpy pattern (brightly clustered large granules in the nucleoli of interphase cells), which tends to homogeneity. In mitotic cells, the antigens remain associated with condensed chromosomal material. The antibodies are rarely found in association with anti-centromere or anti-Scl-70 antibodies.

The presence of 8% anti-Sm antibodies in SSc [1] is highly unlikely regardless of the Black population studied. We were able to find only two reports of anti-Sm antibodies in SSc without overlap syndromes. Clegg et al. [19] detected two anti-Sm-positive patients in 46 SSc cases, using an immunodiffusion technique. Barakat et al. [20] were able to find autoantibodies in 6.3% of 32 SSc patients by ELISA, using the synthetic peptide (fragment 1–20 of the Sm D autoantigen). Numerous other studies, just to mention some of them, did not find any association of anti-Sm autoantibodies with SSc: Bernstein et al. [21] using CIE, immunodiffusion and facilitated immunoprecipitation from HeLa cell extracts in 55 SSc patients, Homma et al. [22] in 24 SSc patients using immunodiffusion, 32P immunoprecipitation and radioimmunoassay, De Rooij et al. [23] using an immunoblotting technique in 33 SSc patients, Bunn et al. [4] in 374 SSc patients using CIE (our observations using CIE and immunoblotting technique).

In the EWRR consensus trials [6], the performance of ELISA for anti-Sm detection was found to be less satisfactory because of the relatively complex molecular structure of the antigen, pointing to the necessity of using at least two methods to confirm anti-Sm activity [6, 10, 24]. Commercial ELISA kits can sometimes give a very high rate of false positive results (unpublished observation of the members of EWRR, including our experience).

We believe that the presence of 42% anti-RNP (U1RNP?) was extremely high as well [1]. The majority of papers describe the presence of anti-U1RNP in SSc patients without overlap syndromes, but the prevalence was regularly not higher than about 10%: 2.5% [21], 7% [19], two of 33 SSc patients [23], one of nine patients, using CIE [25], 15 of 230 SSc patients with passive haemagglutination technique [26]. Bunn et al. [4] were part of the huge series of 374 SSc sera not able to detect any anti-U1RNP activity, using CIE. Therefore, it is very likely that some of the patients diagnosed as SSc had in fact mixed connective tissue disease.

References

  1. Tager RE, Tikly M. Clinical and laboratory manifestations of systemic sclerosis (scleroderma) in Black South Africans. Rheumatology 1999;38:397–400.[Abstract]
  2. Masi AT, Rodnan GP, Medsger TA, Altman RD, D’Angelo WA, Fries JF. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581–90.[ISI][Medline]
  3. Venables PJW. Polymyositis-associated overlap syndrome. Br J Rheumatol 1996;35:305–8.[ISI][Medline]
  4. Bunn CC, Denton CP, Shi-Wen X, Knight C, Black CM. Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol 1998;37:15–20.[ISI][Medline]
  5. Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler MJ, Peebles C. Diversity of antinuclear antibodies in progressive systemic sclerosis. Arthritis Rheum 1980;23:617–25.[ISI][Medline]
  6. Charles PJ, van Venrooij WJ, Maini RN and the Consensus Finding Group for Autoantibodies. The consensus workshops for the detection of autoantibodies to intracellular antigens in rheumatic diseases: 1989–1992. Clin Exp Rheumatol 1992;10:507–11.[ISI][Medline]
  7. Seibold JR. Scleroderma. In: Kelley VN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of rheumatology, 5th edn. Philadelphia: WB Saunders, 1997:1133–62.
  8. Medsger KA. Systemic sclerosis (scleroderma), eosinophilic fasciitis and calcinosis. In: McCarty DJ, ed. Arthritis and allied conditions, 10th edn. Philadelphia: Lea & Febiger, 1985:994–1036.
  9. Humbel RL. Detection of antinuclear antibodies by immunofluorescence. In: van Venrooij WJ, Maini RN, eds. Dordrecht: Kluwer Academic Publishers, 1993:1–11.
  10. Van Venrooij WJ, Charles P, Maini RN. The consensus workshops for the detection of autoantibodies to intracellular antigens in rheumatic diseases. J Immunol Methods 1991;140:181–9.[ISI][Medline]
  11. Bernstein RM, Steigerwald JC, Tan EM. Association of antinuclear and antinucleolar antibodies in progressive systemic sclerosis. Clin Exp Immunol 1982;48:43–51.[ISI][Medline]
  12. Reimer G, Rose KM, Scher U, Tan EM. Autoantibody to RNA polymerase I in scleroderma sera. J Clin Invest 1987;79:65–72.[ISI][Medline]
  13. Beck JS. Variations in the morphological patterns of autoimmune nuclear fluorescence. Lancet 1961;1:1203–5.[Medline]
  14. Oddis CV, Okano Y, Rudert WA et al. Serum autoantibody to nucleolar antigen PM/Scl: clinical and immunogenetic associations. Arthritis Rheum 1992;35:1211–7.[ISI][Medline]
  15. Bautz FA, Blüthner M. The PM/Scl antigens. In: van Venrooij WJ, Maini RN, eds. Manual of biological markers of disease B5. Dordrecht: Kluwer Academic Publishers, 1993:1–17.
  16. Bradwell AR, Stokes RP, Johnson GD. Atlas of Hep-2 patterns. Redditch: KNP Group Ltd, 1995:58.
  17. Ochs RL, Lischwe MA, Spohn WH et al. Fibrillarin: a new protein of the nucleolus identified by autoimmune sera. Biol Cell 1985;54:123–34.[ISI][Medline]
  18. Takeuchi K, Turley SJ, Tan EM, Pollard KM. Analysis of the autoantibody response to fibrillarin in human disease and murine models of autoimmunity. J Immunol 1995;154:961–71.[Abstract/Free Full Text]
  19. Clegg Do, Williams HJ, Singer JZ et al. Early undifferentiated connective tissue disease: II. The frequency of circulating antinuclear antibodies in patients with early rheumatic diseases. J Rheumatol 1991;18:1340–3.[ISI][Medline]
  20. Barakat S, Briand JP, Weber JC, van Regenmortel MHV, Muller S. Recognition of synthetic peptides of Sm-D autoantigen by lupus sera. Clin Exp Immunol 1990;81:256–62.[ISI][Medline]
  21. Bernstein RM, Bunn CC, Hughes GRV, Francoeur AM, Mathews MB. Cellular protein in RNA antigens in autoimmune disease. Mol Biol Med 1984;2:105–20.[Medline]
  22. Homma M, Mimori T, Takeda Y et al. Autoantibodies to the Sm antigen: Immunological approach to clinical aspects of systemic lupus erythematosus. J Rheumatol 1987;14(Suppl. 13):188–93.[Medline]
  23. De Rooij DJ, Habets WJ, Stapel S, van de Putte LB, van Venrooij WJ. Clinical significance of antibodies against nuclear antigens as determined by immunoblotting. Scand J Rheumatol 1985(Suppl);56:93–7.
  24. Hoch SO. The Sm antigens. In: van Venrooij WJ, Maini RN, eds. Manual of biological markers of disease B2. Dordrecht: Kluwer Academic Publishers, 1993:1–29.
  25. Kallenberg CGM, Wouda AA, Hoet MH, van Venrooij WJ. Development of connective tissue disease in patients presenting with Raynaud’s phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann Rheum Dis 1988;47:634–41.[Abstract]
  26. Jacobsen S, Halberg P, Ullman S et al. Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis. Br J Rheumatol 1998;37:39–45.[ISI][Medline]
Accepted 8 September 1999





This Article
Full Text (PDF)
Alert me when this article is cited
Alert me if a correction is posted
Services
Email this article to a friend
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Add to My Personal Archive
Download to citation manager
Disclaimer
Request Permissions
Google Scholar
Articles by Rozman,, B.
Articles by Kveder, T.
PubMed
PubMed Citation
Articles by Rozman,, B.
Articles by Kveder, T.